Navigation Links
Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
Date:4/25/2008

stances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... California (PRWEB) September 17, 2014 ... naturally occurring microorganisms such as bacteria, fungi, and ... into water, methane, biomass, inorganic compounds, carbon dioxide, ... processability, expanding customer base and improved costs, biodegradable ... and economically viable alternative to conventional polymers. Primary ...
(Date:9/17/2014)... 2014 Immunomic Therapeutics, Inc. announced today ... grant to support the continued preclinical development of a ... approximately $255,000 over one year to conduct vaccine validation ... allergy, affect over one million Americans and are the ... nut exposure is also a risk for peanut allergics, ...
(Date:9/17/2014)... -- Hussey Copper , a leader in copper ... announces Gilmour Academy Ice Arena,s conversion of more than ... touch surface to help protect against bacteria.  MD-Cu 29 ... kills greater than 99.9% of MRSA, E-coli and other ... , Innovative Gilmour Academy prepares ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
Breaking Biology Technology:Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
(Date:9/16/2014)... that we inherit certain traits from our parents that ... these genes play out by taking certain drugs or ... what a team of researchers at the Boston University ... of epigenetics research. , Epigenetics regulates gene expression ... histone proteins, which prevent permanent mutations or alterations within ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... 29, 2010) -- Wind turbines may be one of ... larger they also get noisier, become more of an ... solution: ocean-based wind turbines. While offshore turbines already have ... where the tower extends directly into the seabed. That ...
... -- The U.S. Supreme Court ruled 5-4 Monday that a ... the ability to patent software should not be limited. ... the "machine or transformation" test is not the sole test ... however, cannot be patented. IEEE-USA was party to an ...
... the Arctic climate system may be more sensitive to greenhouse ... atmospheric carbon dioxide may be high enough to bring about ... University of Colorado at Boulder, the international study indicated that ... High Arctic during the Pliocene Epoch 2.6 to 5.3 million ...
Cached Biology News:Arctic climate may be more sensitive to warming than thought, says new study 2Arctic climate may be more sensitive to warming than thought, says new study 3Arctic climate may be more sensitive to warming than thought, says new study 4
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: